The Global Acetazolamide
Market, by Formulation (Tablets, Capsules, and Injection), by Application
(Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention,
Heart Failure, and Seizures), By Distribution Channel (Hospital Pharmacy,
Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 191.8
million in 2018, and is projected to exhibit a CAGR of 4.8% during the forecast
period (2018 - 2026).
Acetazolamide is one of the most
preferred medication for glaucoma incidences as it helps in relieving symptoms
and reduces risk of serious complications among patients of glaucoma.
Acetazolamide is sold under different trade names including AZM, Diamox,
Acemox, Evamox, and Setacar. The drug is used to treat glaucoma, epilepsy,
attitude sickness, and heart failure induced edema.
Browse 23 Market Data Tables and
25 Figures spread through 152 Pages and in-depth TOC on "Acetazolamide
Market, by Formulation (Tablets, Capsules and Injection), by Application
(Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention,
Heart Failure and Seizures), By Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Pharmacy) and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2396
Furthermore, key players are
engaged in launching acetazolamide-based products along with gaining regulatory
approval for the same in the market. For instance, in November 2017, Strides
Pharma Global Pte. Ltd. — subsidiary of Strides Shasun Limited—received
approval from the U.S. Food and Drug Administration (FDA) for acetazolamide
tablets, 125 mg and 250 mg, a generic version of Diamox Tablets. Acetazolamide
tablet is used to prevent and reduce the symptoms of altitude sickness and
treat a certain type of eye problem (open-angle glaucoma). In the U.S.,
company’s acetazolamide tablets are marketed by Strides Pharma Inc.
Furthermore, in November 2012, Sagent Pharmaceuticals introduced acetazolamide
for injection, specified for adjunctive treatment of edema due to congestive
heart failure, drug-induced edema, centrencephalic epilepsies, and chronic
simple glaucoma, secondary glaucoma, and preoperatively in acute angle-closure
glaucoma.
Key takeaways of the
Acetazolamide Market:
The global acetazolamide market
is expected to expand at a CAGR of 4.8% during the forecast period (2018 –
2026), owing to high prevalence of glaucoma, edema, and its associated risk
factors such as diabetes, family history of glaucoma, high blood pressure,
among others.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/acetazolamide-market-2396
Among formulation, tablets
segment accounted for major market share in 2017. Acetazolamide is majorly used
in the treatment of glaucoma and altitude sickness, owing to increasing dosing
preference and clinical effectiveness of acetazolamide. For instance, according
to data published in the BMJ journal in September 2012, daily doses of 250 mg,
500 mg, and 750 mg acetazolamide was found to be effective in preventing acute
mountain sickness.
Among applications, glaucoma
segment held major market share, in 2017. Acetazolamide is approved and
increasingly used as carbonic anhydrase inhibitor in the treatment of glaucoma,
by offering substantial pressure relief effect.
Among distribution channel,
hospitals pharmacies segment held major market share in 2017. Hospital
pharmacies act as key channel in distribution of acetazolamide medication to
glaucoma patients who are treated in hospital.
Some of the major players
operating in global acetazolamide market include Teva Pharmaceutical Industries
Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage
Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd.,
Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc.,
Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2396
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment